Multiomics, rooted in research, is increasingly closing in on clinical practice, to the point that institutions should be at least be ready. This was the consensus at CAP TODAY’s roundtable panel on “NGS and Cancer Biomarkers.” Looking at multiple layers of molecular data from the same sample to render all the important interactions

Company Q1 Investor Calls: Most IVD companies have downplayed tariff impact. Small % of revenues affected. Most emphasizing the industry’s having the most advanced supply chains in global industry, one that can shift as tariff targets change. 2 Major Trade Associations: Tariffs are damaging and we need a medical exemption. IVD Industry Blogger:

How are IVD stocks doing in the general market fall? About that huge flu season. A mid-size player reports, which (can be) a measure of the growthiness of the market. And Roche adheres its blood test to its IT-IVD product to aid interpreting results. DiaSorin Reports – Overall Growth, China VP Concerns, Not